Adrenal insufficiency in HIV/AIDS: a review

References

• Kalra S, Sleim H, Kotwal N, et al. Human immunodeficiency virus and the endocrine system. Indian J Endocrinol Metab. 2011;15(4):231–233.
   PubMedGoogle Scholar
• Bhatia E. Adrenal disorders in people with HIV: the highs and lows. Indian J Med Res. 2018;147(2):125–127.
   PubMedGoogle Scholar
• Nassoro DD, Mkhoi LM, Sabi I, Meremo, et al. Adrenal insufficiency: a forgotten diagnosis in HIV/AIDS patients in developing countries. Int J Endocrinol. 2019;(2):1–9. DOI:https://doi.org/10.1155/2019/2342857.
   Google Scholar
• Elliot ER, Theodoraki A, Jain LR, et al. Iatrogenic cushing’s syndrome due to drug between glucocorticoids and the ritonavir or cobicistat containing HIV therapies. Clin Med (Lond). 2016;16(5):412–418.
   PubMed Web of Science ®Google Scholar
• Williams D. Secondary adrenal insufficiency from steroid use and co-prescribing of cytochrome p450 3A4 inhibitors. HIV Med. 2019;20(5):e10–e11.
   PubMed Web of Science ®Google Scholar
• Kedem E. Iatrogenic cushing’s syndrome due to coadministration of ritonavir and inhaled budesonide in an asthmatic human immunodeficiency virus infected patient. J Asthma. 2010;47(7):830.
   PubMed Web of Science ®Google Scholar
• Gray D. Adrenal suppression and cushing’s syndrome secondary to ritonavir and budesonide. S Afr Med J. 2010;100(5):296.
   PubMed Web of Science ®Google Scholar
• Yombi JC. Iatrogenic cushing’s syndrome and secondary adrenal insufficiency after a single intra-articular administration of triamcinolone acetonide in HIV-infected patients treated with ritonavir. Clin Rheumatol. 2008;27(Suppl 2):S79.
   PubMedGoogle Scholar
• Dork K. Adrenal suppression due to an interaction between ritonavir and injected triamcinolone: a case report. AIDS Res Ther. 2009;6:10.
   PubMedGoogle Scholar
• Rainsbury PG. Ritonavir and topical ocular corticosteroid induced cushing’s syndrome in an adolescent with HIV-1 infection. Pediatr Infect Dis J. 2017;36(5):502.
   PubMedGoogle Scholar
• Wassner C. Iatrogenic adrenal insufficiency secondary to combination therapy with elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and interlaminar triamcinolone injection in an AIDS patient. J Int Assoc Provid AIDS Care. 2017;16(6):535.
   PubMedGoogle Scholar
• Makaram N. Exogenous steroid-induced hypoadrenalism in a person living with HIV caused by a drug-drug interaction between cobicistat and intrabursal triamcinolone. BMJ Case Rep. 2018;11(1). DOI:https://doi.org/10.1136/bcr-2018-226912.
   Google Scholar
• Besemer F. Hypothalamic-pituitary-adrenal axis suppression by inhaled or nasal corticosteroids in HIV-infected patients. Int J Clin Pharm. 2020;42:347–350.
   PubMed Web of Science ®Google Scholar
• Smith SM. The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. Dialogues Clin Neurosci. 2006;8(4):383–395.
   PubMedGoogle Scholar
• Gaillard RC. Neuroendocrine-immune system interactions: the immune-hypothalamo-pituitary-adrenal axis. Trends Endocrinol Metab. 1994;5(7):303–309.
   PubMed Web of Science ®Google Scholar
• Appay V. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol. 2008;214(2):231–241.
   PubMed Web of Science ®Google Scholar
• Zapanti E, Terzidis K, Chrousos G, et al. Dysfunction of the hypothalamic-pituitary-adrenal axis in HIV infection and disease. Hormones (Athens). 2008;7(3):205–216.
   PubMedGoogle Scholar
• Bons J, Moreau L, Lefebvre H, et al. Adrenal disorders in human immunodeficiency virus (HIV) infected patients. Ann Endocrinol (Paris). 2013;74(5–6):508–514.
   PubMed Web of Science ®Google Scholar
• Villette JM, Bourin P, Doinel C, et al. Circadian variations in plasma levels of hypophyseal, adrenocortical and testicular hormones in men infected with human immunodeficiency virus. J Clin Endocrinol Metab. 1990;70(3):572–577.
   PubMed Web of Science ®Google Scholar
• Mayo J, Collazos J, Martínez E, et al. Adrenal function in the human immunodeficiency virus-infected patient. Arch Intern Med. 2002;162(10):1095–1098.
   PubMedGoogle Scholar
• Costa A, Nappi RE, Polatti F, et al. Stimulating effect of HIV-1 coat protein gp120 on corticotropin-releasing hormone and arginine vasopressin in the rat hypothalamus: involvement of nitric oxide. Exp Neurol. 2000;166(2):376–384.
   PubMed Web of Science ®Google Scholar
• Pozzoli G. HIV1 Gp120 protein modulates corticotropin releasing factors synthesis and release via the stimulation of its mRNA from the rat hypothalamus in vitro: involvement of inducible nitric oxide synthase. J Neuroimmunol. 2001;118(2):268–276.
   PubMed Web of Science ®Google Scholar
• Sokoya T, Steel HC, Nieuwoudt M, et al. HIV as a cause of immune activation and activation and immunesenescence. Mediators Inflamm. 2017;2017:6825493.
   PubMed Web of Science ®Google Scholar
• Chen CCG, Parker CR. Adrenal androgens and the immune system. Semin Reprod Med. 2004;22(4):369–377.
   PubMed Web of Science ®Google Scholar
• Miller WL, Auchus RJ, Geller DH, et al. The regulation of 17,20 lyase activity. Steroids. 1997;62(1):133–142.
   PubMed Web of Science ®Google Scholar
• Hales DB. Interleukin-1 inhibits leydig cell steroidogenesis primarily by decreasing 17 alpha-hydroxylase/C17-20 lyase cytochrome P450 expression. Endocrinology. 1992;131(5):2165–2172.
   PubMed Web of Science ®Google Scholar
• Jäättelä M, Ilvesmäki V, Voutilainen R, et al. Tumour necrosis factor as a potent inhibitor of adrenocorticotropin-induced cortisol production and steroidogenic P450 enzyme gene expression in cultured human fetal adrenal cells. Endocrinology. 1991;128(1):623–629.
   PubMed Web of Science ®Google Scholar
• Grinspoon S, Corcoran C, Stanley T, et al. Mechanisms of androgen deficiency in human immunodeficiency virus-infected women with the wasting syndrome. J Clin Endocrinol Metab. 2001;86(9):4120–4126.
   PubMed Web of Science ®Google Scholar
• Grinspoon SK, Bilezikian JP. HIV disease and the endocrine system. N Engl J Med. 1992;327(19):1360–1365.
   PubMed Web of Science ®Google Scholar
• Schürmeyer TH, Müller V, von zur Mühlen A, et al. Thyroid and adrenal function in HIV-infected outpatients. Eur J Med Res. 1997;2(5):220–226.
   PubMedGoogle Scholar
• Lambert M, Zech F, De Nayer P, et al. Elevation of serum thyroxine-binding globulin (but not of cortisol-binding globulin and sex hormone-binding globulin) associated with the progression of human immunodeficiency virus infection. Am J Med. 1990;89(6):748–751.
   PubMed Web of Science ®Google Scholar
• Martin ME, Benassayag C, Amiel C, et al. Alterations in the concentrations and binding properties of sex steroid binding protein and corticosteroid-binding globulin in HIV+ patients. J Endocrinol Invest. 1992;15(8):597–603.
   PubMed Web of Science ®Google Scholar
• Norbiato G, Galli M, Righini V, et al. 4 The syndrome of acquired glucocorticoid resistance in HIV infection. Baillieres Clin Endocrinol Metab. 1994;8(4):777–787.
   PubMedGoogle Scholar
• Norbiato G. Endocrine, metabolic, and immunologic components of HIV infection. Ann N Y Acad Sci. 2012;1262(1):51–55.
   PubMedGoogle Scholar
• Vagnucci AH, Winkelstein A. Circadian rhythm of lymphocytes and their glucocorticoid receptors in HIV-infected homosexual men. J Acquir Immune Defic Syndr (1988). 1993;6(11):1238–1247.
   PubMed Web of Science ®Google Scholar
• Kino T, Su YA, Chrousos JP, et al. Human glucocorticoid receptor (GR) isoform β: recent understanding of its potential implicationsin physiology and pathophysiology. Cell Mol Life Sci. 2009;66(21):3435–3448.
   PubMed Web of Science ®Google Scholar
• Contoreggi C, Chrousos JP, Di Mascio M, et al. Chronic distress and the vulnerable host: a new target for HIV treatment and prevention?. Neurobehav HIV Med. 2016;(7):53–75. DOI:https://doi.org/10.2147/NBHIV.S86309.
   Google Scholar
• Baschant U, Tuckermann J. The role of the glucocorticoid receptor in inflammation and immunity. J Steroid Biochem Mol Biol. 2010;120(2–3):69–75.
   PubMed Web of Science ®Google Scholar
• Emilie D. Cytokines in HIV infection. Int J Immunopharmacol. 1994;16(5–6):391–396.
   PubMed Web of Science ®Google Scholar
• Clerici M, Trabattoni D, Piconi S, et al. A possible role for the cortisol/anticortisols imbalance in the progression of human immunodeficiency virus. Psychoneuroendocrinology. 1997;22(Suppl1):S27–31.
   PubMedGoogle Scholar
• Wisniewski TL, Hilton CW, Morse EV, et al. The relationship of serum DHEA-S and cortisol levels to measures of immune function in human immunodeficiency virus-related illness. Am J Med Sci. 1993;305(2):79–83.
   PubMed Web of Science ®Google Scholar
• Christeff N, Gherbi N, Mammes O, et al. Serum cortisol and DHEA concentrations during HIV infection. Psychoneuroendocrinology. 1997;22(Suppl1):S11–8.
   PubMedGoogle Scholar
• Sherman MP, de Noronha CM, Pearce D, et al. Human immunodeficiency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G(2) cell cycle arrest. J Virol. 2000;74(17):8159–8165.
   PubMed Web of Science ®Google Scholar
• Findling JW, Buggy BP, Gilson IH, et al. Longitudinal evaluation of adrenocortical function in patients infected with the human immunodeficiency virus. J Clin Endocrinol Metab. 1994;79(4): 1091–1096.
   PubMed Web of Science ®Google Scholar
• Freda PU, Papadopoulos AD, Wardlaw SL, et al. Spectrum of adrenal dysfunction in patients with acquired immunodeficiency syndrome Evaluation of Adrenal and Pituitary Reserve with ACTH and Corticotropin-Releasing Hormone Testing. Trends Endocrinol Metab. 1997;8(5): 173–180.
   PubMed Web of Science ®Google Scholar
• Biglino A, Limone P, Forno B, et al. Altered adrenocorticotropin and cortisol response to corticotropin-releasing hormone in HIV-1 infection. Eur J Endocrinol. 1995;133(2):173–179.
   PubMed Web of Science ®Google Scholar
• Arlt W, Allolio B. Adrenal insufficiency. Lancet. 2003;361(9372):1881–1893.
   PubMed Web of Science ®Google Scholar
• Grinspoon SK, Biller BM. Clinical review 62: laboratory assessment of adrenal insufficiency. J Clin Endocrinol Metab. 1994;79(4):923–931.
   PubMed Web of Science ®Google Scholar
• Wallace I, Cunningham S, Lindsay J, et al. The diagnosis and investigation of adrenal insufficiency in adults. Ann Clin Biochem. 2009;46(5):351–367.
   PubMedGoogle Scholar
• Salvatori R. Adrenal insufficiency. JAMA. 2005;294(19):2481–2488.
   PubMed Web of Science ®Google Scholar
• Schmidt IL. Diagnosis of adrenal insufficiency: evaluation of the corticotropin-releasing hormone test and basal serum cortisol in comparison to the insulin tolerance test in patients with hypothalamic–pituitary – adrenal disease. J Clin Endocrinol Metab. 2003;88:4193–4198.
   PubMed Web of Science ®Google Scholar
• Charmandari E, Nicolaides NC, Chrousos GP, et al. Adrenal insufficiency. Lancet. 2014;383(9935):2152–2167.
   PubMed Web of Science ®Google Scholar
• Hannibal KE, Bishop MD. Chronic stress, cortisol dysfunction and pan: a psychoneuroendocrine rationale for stress management in pain rehabilitation. Phys Ther. 2014;94(12):1816–1825.
   PubMed Web of Science ®Google Scholar
• McEwen BS. Central effects of stress hormones in health and disease: understanding the protective and damaging effects of stress and stress mediators. Eur J Pharmacol. 2008;583(2–3):174–185.
   PubMed Web of Science ®Google Scholar
• Fries E, Hesse J, Hellhammer J, et al. A new view on hypocortisolism. Psychoneuroendocrinology. 2005;30(10):1010–1016.
   PubMed Web of Science ®Google Scholar
• Joëls M. Impact of glucocorticoids on brain function: relevance for mood disorders. Psychoneuroendocrinology. 2011;36(3):406–414.
   PubMed Web of Science ®Google Scholar
• McEwen BS, Kalia M. The role of corticosteroids and stress in chronic pain conditions. Metabolism. 2010;59(suppl 1):S9–S15.
   PubMedGoogle Scholar
• Yang N, Ray DW, Matthews LC, et al. Current concepts in glucocorticoid resistance. Steroids. 2012;77(11):1041–1049.
   PubMed Web of Science ®Google Scholar
• Naggirnya AB, Mujugira A, Meya DB, et al. Functional adrenal insufficiency among tuberculosis-human immunodeficiency virus co-infected patients: a cross-sectional study in Uganda. BMC Res Notes. 2020;13(1):224.
   Google Scholar
• Nacher M, Alsibai KD, Valdes A, et al. HIV-associated disseminated histoplasmosis and rare adrenal involvement: evidence of absence or absence of evidence. Front Cell Infect Microbiol. 2021;11:619459.
   PubMed Web of Science ®Google Scholar
• Varon J, Chen K, Sternbach GL, et al. Rupert waterhouse and carl friderichsen: adrenal apoplexy. J Emerg Med. 1998;16(4):643–647.
   PubMedGoogle Scholar
• Waterhouse R. A case of suprarenal apoplexy. Lancet. 1911;177(4566):577–578.
   Google Scholar
• Friderichsen C. Waterhouse-friderichsen syndrome (W.-F.S.). Acta Endocrinol (Copenh). 1955;18(4):482–492.
   PubMedGoogle Scholar
• Hamilton D, Harris MD, Foweraker J, et al. Waterhouse-friderichsen syndrome as a result of non-meningococcal infection. J Clin Pathol. 2004;57(2):208–209.
   PubMed Web of Science ®Google Scholar
• Paolo WF Jr, Nosanchuk JD. Adrenal infections. Int J Infect Dis. 2006;10(5):343–353.
   PubMed Web of Science ®Google Scholar
• Siejka A, Barabutis N. Adrenal insufficiency in the covid-19 era. Am J Physiol Endocrinol Metab. 2021;320(E784–E785). DOI:https://doi.org/10.1152/ajpendo.00061.2021.
   Google Scholar
• Ferraù F, Ceccato F, Cannavó S, et al. What we have to know about corticosteroids use during Sars-Cov-2 infection. J Endocrinol Invest. 2021;44(4):693–701.
   PubMed Web of Science ®Google Scholar
• AlmeidaMQ, Mendonca BB. Adrenal insufficiency and glucocorticoid use during the COVID-19 pandemic. Clinics (Sao Paulo). 2020;75:e2022.
   PubMed Web of Science ®Google Scholar
• Pal R, Banerjee M. COVID-19 and the endocrine system: exploring the unexplored. J Endocrinol Invest. 2020;3:9.
   Google Scholar
• Zinserling VA. Inflammatory cell infiltration of adrenals in COVID-19. Horm Metab Res. 2020;52(9):639–641.
   PubMedGoogle Scholar
• Álvarez-Troncoso J. Case report: COVID-19 with bilateral adrenal haemorrhage. Am J Trop Med Hyg. 2020;103(3):1156–1157.
   PubMed Web of Science ®Google Scholar
• Santana MF. Case report: adrenal pathology findings in severe COVID-19: an autopsy result. Am J Trop Med Hyg. 2020;103(4):1604–1607.
   PubMed Web of Science ®Google Scholar
• Meya DB, Katabira E, Otim M, et al. Functional adrenal insufficiency among critically ill patients with human immunodeficiency virus in a resource-limited setting. Afr Health Sci. 2007;7(2):101–107.
   PubMedGoogle Scholar
• Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61(3):246–255.
   PubMed Web of Science ®Google Scholar
• Van Der Pas R, Hofland LJ, Hofland J, et al. Fluconazole inhibits human adrenocortical steroidogenesis in vitro. J Endocrinol. 2012;215(3):403–412.
   PubMed Web of Science ®Google Scholar
• Canteros TM, De Miguel V, Fainstein-Day P. Fluconazole treatment in severe ectopic cushing syndrome. Endocrinol Diabetes Metab Case Rep. 2019;2019(1):19-0020.
   Google Scholar
• Pal R. COVID-19, hypothalamo-pituitary-adrenal axis and clinical implications. Endocrine. 2020;68(2):251–252.
   PubMed Web of Science ®Google Scholar
• Samaras K, Pett S, Gowers A, et al. Iatrogenic cushing’s syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases. J Clin Endocrinol Metab. 2005;90(7):4394–4398.
   PubMed Web of Science ®Google Scholar
• Zhou S, Chan SY, Goh BC, et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005;44(3):279–304.
   PubMed Web of Science ®Google Scholar
• Granfors MT, Wang J, Kajosaari LI, et al. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006;98(1):79–85.
   PubMed Web of Science ®Google Scholar
• Foisy MM, Yakiwchuk EMK, Chiu I, et al. Adrenal suppression and cushing’s syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature. HIV Med. 2008;9(6):389–396.
   PubMed Web of Science ®Google Scholar
• Levine D, Ananthakrishnan S, Garg A. Iatrogenic cushing syndrome after a single intramuscular corticosteroid injection and concomitant protease inhibitor therapy. J Am Acad Dermatol. 2011;65(4):877–878.
   PubMed Web of Science ®Google Scholar
• Sadarangani S, Berg ML, Mauck W, et al. Iatrogenic cushing syndrome secondary to ritonavir-epidural triamcinolone interaction: an illustrative case and review. Interdiscip Perspect Infect Dis. 2014;2014:849432.
   PubMedGoogle Scholar
• Joe EK. Cushing syndrome secondary to topical glucocorticoids. Dermatol Online J. 2003;9(4):16.
   PubMedGoogle Scholar
• Penzak SR, Formentini E, Alfaro RM, et al. Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisolone administration to healthy volunteers. J Acquir Immune Defic Syndr. 2005;15(40):573–580.
   Google Scholar
• Paragliola RM, Papi G, Pontecorvi A, et al. Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis. Int J Mol Sci. 2017;18(10):2201.
   Web of Science ®Google Scholar
• Saberi P, Phengrasamy T, Nguyen DP. Inhaled corticosteroid use in HIV-positive individuals taking protease inhibitors: a review of pharmacokinetics, case reports and clinical management. HIV Med. 2013;14(9):519–529.
   PubMed Web of Science ®Google Scholar
• Henzen C, Suter A, Lerch E, et al. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet. 2000;355(9203):542–545.
   PubMed Web of Science ®Google Scholar
• Policola C, Stokes V, Karavitaki N, et al. Adrenal insufficiency in acute oral opiate therapy. Endocrinology, diabetes & metabolism case reports. 2014; 130071.
   Google Scholar
• Ducat E, Ray B, Bart G, et al. Mu-opioid receptor A118G polymorphism in healthy volunteers affects hypothalamic-pituitary-adrenal axis adrenocorticotropic hormone stress response to metyrapone. Addict Biol. 2013;18(2):325–331.
   PubMed Web of Science ®Google Scholar
• Volavka J, Bauman J, Pevnick J, et al. Short-term hormonal effects of naloxone in man. Psychoneuroendocrinology. 1980;5(3):225–234.
   PubMed Web of Science ®Google Scholar
• Volavka J, Cho D, Mallya A, et al. Naloxone increases ACTH and cortisol in man. N Engl J Med. 1979;300:1056–1057.
   PubMed Web of Science ®Google Scholar
• Flaman AS. The effect of interferon-α on the expression of cytochrome P450 3A4 in human hepatoma cells. Toxicol Appl Pharmacol. 2011;253(2):130–136.
   PubMed Web of Science ®Google Scholar
• Raison CA. Interferon-α effects on diurnal hypothalamic– pituitary–adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol Psychiatry. 2010;15(5):535–547.
   PubMed Web of Science ®Google Scholar
• Carelli M. Modulation of constitutive and inducible hepatic cytochrome(s) P-450 by interferon β in mice. J Hepatol. 1996;24(2):230–237.
   PubMed Web of Science ®Google Scholar
• Goebel M, Baase J, Pithan V, et al. Acute interferon β-1b administration alters hypothalamic-pituitary-adrenal axis activity, plasma cytokines and leukocyte distribution in healthy subjects. Psychoneuroendocrinology. 2002;27(8):881–892.
   PubMed Web of Science ®Google Scholar
• Then Bergh F. Acute and chronic neuroendocrine effects of interferon-beta 1a in multiple sclerosis. Clin Endocrinol. 2007;66(2):295–303.
   PubMed Web of Science ®Google Scholar
• Akase IE, Habib AG, Bakari AG, et al. The prevalence and clinical profile of adrenocortical deficiency among HIV infected persons in Northern Nigeria. Afr Health Sci. 2019;19(2):1947–1952.
   PubMed Web of Science ®Google Scholar
• Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of adrenal insufficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(2):364–389.
   PubMed Web of Science ®Google Scholar
• Toro CA, Campuzano Maya G, Latorre Sierra G. Dynamic testing in endocrinology: adrenal insufficiency. Medicina & Laboratorio. 2009;15(05–06): 211–232.
   Google Scholar
• Hägg E, Asplund K, Lithner F, et al. Value of basal plasma cortisol assays in the assessment of pituitary-adrenal insufficiency. Clin Endocrinol (Oxf). 1987;26(2):221–226.
   PubMed Web of Science ®Google Scholar
• Manosroi W, Phimphilai M, Khorana J, et al. Diagnostic performance of basal cortisol level at 0900-1300 hours in adrenal insufficiency. PLoS One. 2019;14(11):e0225255.
   PubMed Web of Science ®Google Scholar
• Novoa DM, Torres VE, Palacios GN, et al. Guidelines for the diagnosis and treatment of adrenal insufficiency in adults. Endocrinol Nutr. 2014;61(Supl.1):1–34.
   Google Scholar
• Struja T, Briner L, Meier A, et al. Diagnostic accuracy of basal cortisol level to predict adrenal insufficiency in cosyntropin testing: results from an observational cohort study with 804 patients. Endocr Pract. 2017;23(8):949–961.
   PubMed Web of Science ®Google Scholar
• Wu J, Hsu S, Ku S, et al. Adrenal insufficiency in prolonged critical illness. Crit Care. 2008;12(3):R65.
   PubMed Web of Science ®Google Scholar
• Cooper MS, Steward PM. Corticosteroid insufficiency in acutely ill patient. N Engl J Med. 2003;348:727–734.
   PubMed Web of Science ®Google Scholar
• Zaloga GP, Marik P. Hypothalamic-pituitary-adrenal insufficiency. Crit Care Clin. 2001;17(1):25–41.
   PubMed Web of Science ®Google Scholar
• Moraes RB, Czepielewski MA, Friedman G, et al. Diagnosis of adrenal failure in critically ill patients. Arq Bras Endocrinol Metab. 2011;55(5):295-302.
   PubMedGoogle Scholar
• Marik PE, Pastores SM, Annane D, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American college of critical care medicine. Crit Care Med. 2008;36(6):1937–1949.
   PubMed Web of Science ®Google Scholar
• Dickstein G, Shechner C, Nicholson WE, et al. Adrenocorticotropin stimulation test: effects of basal cortisol level, time of day, and suggested new sensitive low dose test. J Clin Endocrinol Metab. 1991;72(4):773–778.
   PubMed Web of Science ®Google Scholar
• May ME, Carey RM. Rapid adrenocorticotropic hormone test in practice. Retrospective review. Am J Med. 1985;79(6):679–684.
   PubMed Web of Science ®Google Scholar
• Oelkers W. The role of high- and low-dose corticotropin tests in the diagnosis of secondary adrenal insufficiency. Eur J Endocrinol. 1998;139(6):567–570.
   PubMed Web of Science ®Google Scholar
• Magnotti M, Shimshi M. Diagnosing adrenal insufficiency: which test is best–the 1-microg or the 250-microg cosyntropin stimulation test?. Endocr Pract. 2008;14:233–238.
   PubMedGoogle Scholar
• Dickstein G, Spigel D, Arad E, et al. One microgram is the lowest ACTH dose to cause a maximal cortisol response. There is no diurnal variation of cortisol response to submaximal ACTH stimulation. Eur J Endocrinol. 1997;137(2):172–175.
   PubMed Web of Science ®Google Scholar
• Ceccato F, Scaroni C. Central adrenal insufficiency: open issues regarding diagnosis and glucocorticoid treatment. Clin Chem Lab Med. 2019;57(8):1125–1135.
   PubMed Web of Science ®Google Scholar
• Dekkers OM, Timmermans JM, Smit JWA, et al. Comparison of the cortisol responses to testing with two doses of ACTH in patients with suspected adrenal insufficiency. Eur J Endocrinol. 2011;164(1):83–87.
   PubMed Web of Science ®Google Scholar
• Kazlauskaite R, Evans AT, Villabona CV, et al. Corticotropin tests for hypothalamic-pituitary-adrenal insufficiency: a metaanalysis. J Clin Endocrinol Metab. 2008;93(11):4245–4253.
   PubMed Web of Science ®Google Scholar
• Dorin RI, Qualls CR, Crapo LM, et al. Diagnosis of adrenal insufficiency. Ann Intern Med. 2003;139(3):194–204.
   PubMed Web of Science ®Google Scholar
• Abdu TA, Elhadd TA, Neary R, et al. Comparison of the low dose short synacthen test (1 microg), the conventional dose short synacthen test (250 microg) and the insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in patients with pituitary disease. J Clin Endocrinol Metab. 1999;84(3):838–848.
   PubMed Web of Science ®Google Scholar
• Maghnie M, Uga E, Temporini F, et al. Evaluation of adrenal function in patients with growth hormone deficiency and hypothalamic-pituitary disorders: comparison between insulin-induced hypoglycemia, low-dose ACTH, standard ACTH and CRH stimulation tests. Eur J Endocrinol. 2005;152(5):735–741.
   PubMed Web of Science ®Google Scholar
• Ospina NS, Al Nofal A, Bancos I, et al. ACTH stimulation tests for the diagnosis of adrenal insufficiency: systematic review and meta-analysis. J Clin Endocrinol Metab. 2016;101(2):427–434.
   PubMed Web of Science ®Google Scholar
• Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(11):3888–3921.
   PubMed Web of Science ®Google Scholar
• Kim YJ. Stimulated salivary cortisol as a noninvasive diagnostic tool for adrenal insufficiency. Endocrinol Metab (Seoul). 2020;25(3):628–635.
   Google Scholar
• Perogamvros I. Measurement of salivary cortisol with liquid chromatography-tandem mass spectrometry in patients undergoing dynamic endocrine testing. Clin Endocrinol (Oxf). 2010;72(1):17–21.
   PubMed Web of Science ®Google Scholar
• Langelaan MLP. Salivary cortisol in the diagnosis of adrenal insufficiency: cost-effective and patient friendly. Endocr Connect. 2018;7(4):560–566.
   PubMed Web of Science ®Google Scholar
• Baruah MP. Sub-clinical addison’s disease. Indian J Endocrinol Metab. 2012;16(Suppl 2):S176–S177.
   PubMedGoogle Scholar
• Betterle C, Scalici C, Prescotto F, et al. The natural history of adrenal function in autoimmune patients with adrenal autoantibodies. J  Endocrinol. 1988;117(3):467–475.
   PubMed Web of Science ®Google Scholar
• Coco G, Dal Pra C, Presotto F, et al. Estimated risk for developing autoimmune addison’s disease in patients with adrenal cortex autoantibodies. J Clin Endocrinol Metab. 2006;91(5):1637–1645.
   PubMed Web of Science ®Google Scholar
• Pazderska A, Pearce SHS. Adrenal insufficiency – recognition and management. Clin Med (Lond). 2017;17(3):258–262.
   PubMed Web of Science ®Google Scholar
• Baker PR, Nanduri P, Pa G, et al. Predicting the onset of addison’s disease: ACTH, renin, cortisol and 21-hydroxylase autoantibodies. Clin Endocrinol. 2012;76:617–624.
   PubMed Web of Science ®Google Scholar
• Jones SL, Trainer PJ, Perry L, et al. An audit of the insulin tolerance test in adult subjects in an acute investigation unit over one year. Clin Endocrinol (Oxf). 1994;41(1):123–128.
   PubMed Web of Science ®Google Scholar
• Liew A, Agha A, Finucane F, et al. The insulin tolerance test (ITT) in clinical practice: the experience of a busy pituitary unit. Presented at the 23rd Joint Meeting of the British Endocrine Societies with the European Federation of Endocrine Societies BES 2004. Endocrine Abstracts (2004) 7P145.
   Google Scholar
• Yuen KCJ. Growth hormone stimulation tests in assessing adult growth hormone deficiency. 2019. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Grossman A, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc; 2000.
   Google Scholar
• Fiad TM, Kirby JM, Cunningham SK, et al. The overnight single-dose metyrapone test is a simple and reliable index of the hypothalamic-pituitary adrenal axis. Clin Endocrinol (Oxf). 1994;40(5):603–609.
   PubMed Web of Science ®Google Scholar
• Monaghan PJ, Owen LJ, Trainer PJ, et al. Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyrapone. Ann Clin Biochem. 2011;48(5):441–446.
   PubMedGoogle Scholar
• Ach T, Yosra H, Jihen M, et al. Cortisol cut-points for the glucagon stimulation test in the evaluation of hypothalamic pituitary adrenal axis. Endocr J. 2018;65(9):935–942.
   PubMed Web of Science ®Google Scholar
• Husebye ES, Allolio B, Arlt W, et al. Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J Intern Med. 2014;275(2):104–115.
   PubMed Web of Science ®Google Scholar
• Rahvar AH, Haas CS, Danneberg S, et al. Increased cardiovascular risk in patients with adrenal insufficiency: a short review. Biomed Res Int. 2017;2017:3691913.
   PubMed Web of Science ®Google Scholar
• Charmandari E, Kino T, Chrousos GP, et al. Familial/sporadic glucocorticoid resistance: clinical phenotype and molecular mechanisms. Ann N Y Acad Sci. 2004;1024:168–181.
   PubMed Web of Science ®Google Scholar
• Polito A, Aboab J, Annane D, et al. Adrenal insufficiency in sepsis. Rev Bras Ter Intensiva. 2006;18(1):86–94.
   PubMedGoogle Scholar
• Norbiato G, Bevilacqua M, Vago T, et al. Glucocorticoid resistance and the immune function in the immunodeficiency syndrome. Ann N Y Acad Sci. 1998;840(1):835–847.
   PubMedGoogle Scholar
• Kameyama K, Tanaka S, Ishida Y, et al. Interferons modulate the expression of the hormone receptors on the surface of murine melanoma cells. J Clin Invest. 1989;83(1):213–221.
   PubMed Web of Science ®Google Scholar
• Zaid D, Greenman Y. Human immunodeficiency virus infection and the endocrine system. Endocrinol Metab (Seoul). 2019;34(2):95–105.
   PubMedGoogle Scholar
• Arlt W. Society for endocrinology clinical committee. Society for endocrinology endocrine emergency guidance: emergency management of acute adrenal insufficiency (adrenal crisis) in adult patients. Endocr Connect. 2016;5(5):G1–G3.
   PubMed Web of Science ®Google Scholar
• Dineen R, Thompson CJ, Sherlock M, et al. Adrenal crisis: prevention and management in adult patients. Ther Adv Endocrinol Metab. 2019;10:2042018819848218.
   Web of Science ®Google Scholar
• Shenker Y, Skatrud JB. Adrenal insufficiency in critically ill patients. Am J Respir Crit Care Med. 2001;163(7):1520–1523.
   PubMed Web of Science ®Google Scholar
• Boyd SD, Hadigan C, McManus M, et al. Influence of low-dose ritonavir with and without darunavir on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone. J Acquir Immune Defic Syndr. 2013;63(3):355–361
   PubMed Web of Science ®Google Scholar
• Hopkins RL, Leinung MC. Exogenous cushing’s syndrome and glucocorticoid withdrawal. Endocrinol Metab Clin North Am. 2005;34(2):371–384.
   PubMed Web of Science ®Google Scholar
• Abraham G, Demiraj F, Ungemach FR, et al. Comparison of the hypothalamic-pituitary-adrenal axis susceptibility upon single-dose i.m. depot versus long-acting i.v. triamcinolone acetonide therapy: a direct pharmacokinetic correlation. J Endocrinol. 2006;191(2):491–496.
   PubMed Web of Science ®Google Scholar
• Hyle EP, Wood BR, Backman ES, et al. High frequency of hypothalamic-pituitary-adrenal axis dysfunction after local corticosteroid injection in HIV-infected patients on protease inhibitor therapy. J Acquired Immune Deficiency Syndromes. 2013;63(5):602–608.
   PubMed Web of Science ®Google Scholar
• Henderson E, Yang JY, Schwartz A, et al. Dehydroepiandrosterone (DHEA) and synthetic DHEA analogues are modest inhibitors of HIV-1 IIIB replication. AIDS Res Hum Retroviruses. 1992;8(5):625–631.
   PubMed Web of Science ®Google Scholar
• James JS. DHEA: modest viral load reduction in patients. AIDS Treat News. 1996;(no252):7–8.
   PubMedGoogle Scholar
• Abrams DI, Shade SB, Couey P, et al. Dehydroepiandrosterone (DHEA) on HIV replication and host immunity: a randomised placebo-controlled study. AIDS Res Hum Retroviruses. 2007;23(1):77–85.
   PubMed Web of Science ®Google Scholar
• Rabkin JG, Ferrando SJ, Wagner GJ, et al. DHEA treatment for HIV+ patients: effects on mood, androgenic and metabolic parameters. Psychoneuroendocrinology. 2000;25(1):53–68.
   PubMed Web of Science ®Google Scholar
• Weinberg M, Schambelan M. Pituitary and adrenal gland dysfunction in patients with HIV. UpToDate. Retrieved January 27, 2021 from Pituitary and adrenal gland dysfunction in patients with HIV - UpToDate. 2019.
   Google Scholar
• Barroso J, Voss JG. Fatigue in HIV and AIDS: an analysis of evidence. J Assoc Nurses AIDS Care. 2013;24(1Suppl):S5–S14.
   PubMedGoogle Scholar
• Jong E, Oudhoff LA, Epskamp C, et al. Predictors and treatment strategies of HIV-related fatigue in the combined antiretroviral therapy era. AIDS. 2010;24(10):1387–1405.
   PubMed Web of Science ®Google Scholar
• Phillips KD, Sowell RL, Rojas M, et al. Physiological and psychological correlates of fatigue in HIV disease. Biol Res Nurs. 2004;6(1):59–74.
   PubMedGoogle Scholar
• van Welzen BJ, De Vries TI, Arends JE, et al. The use of corticosteroids does not influence CD4+ lymphocyte recovery in HIV-infected patients with advanced immunodeficiency. AIDS Care. 2020;32(6):701–704.
   PubMed Web of Science ®Google Scholar
• Fernández-Sánchez M, Iglesias MC, Ablanedo-Terrazas Y, et al. Steroids are a risk factor for kaposi’s sarcoma-immune reconstitution inflammatory syndrome and mortality in HIV infection. AIDS. 2016;30(6):909–914.
   PubMed Web of Science ®Google Scholar